J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Johnson & Johnson beat first-quarter earnings expectations and raised full-year guidance, helped by strong demand for Darzalex and Tremfya. That strength more than offset a steep decline in Stelara sales, pointing to solid underlying fundamentals despite a major product headwind. The print is likely supportive for the stock, with the guidance raise the key positive takeaway.

Analysis

Johnson & Johnson beat first-quarter earnings expectations and raised full-year guidance, helped by strong demand for Darzalex and Tremfya. That strength more than offset a steep decline in Stelara sales, pointing to solid underlying fundamentals despite a major product headwind. The print is likely supportive for the stock, with the guidance raise the key positive takeaway.